SCHEMBL6539334

SCHEMBL6539334

CCCCCC(Oc1[c]cccc1)Oc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.36
CSNK1E P49674 1/20 0.35
CNR2 P34972 1/20 0.34
CTRC Q99895 1/20 0.33
SLC6A4 P31645 2/20 0.33
MLNR O43193 1/20 0.33
NR1I2 O75469 1/20 0.33
ESR1 P03372 1/20 0.33
NR3C1 P04150 1/20 0.33
PGR P06401 1/20 0.33
ADRB2 P07550 1/20 0.33
CHRM2 P08172 1/20 0.33
ADRB1 P08588 1/20 0.33
HTR1A P08908 1/20 0.33
ADRA2A P08913 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
CHRM1 P11229 1/20 0.33
DRD2 P14416 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6539534 0.90 PPARG (0.33) LTA4HSLC6A4PPARGPPARA
SCHEMBL4445054 0.84 LTA4H (0.47) LTA4HCSNK1ECNR2CTRCSLC6A4
SCHEMBL6539572 0.83 SLC6A4 (0.32) LTA4HSLC6A4ALDH1A1LMNA
SCHEMBL8032386 0.83 CSNK1E (0.46) LTA4HCSNK1ECNR2CTRCSLC6A4
SCHEMBL6132895 0.81 CA2 (0.31) ALDH1A1CYP3A4
SCHEMBL4453544 0.79 LTA4H (0.47) LTA4HCSNK1ECNR2SLC6A4MLNR
SCHEMBL2776003 0.78 PRSS1 (0.38) CSNK1ECNR2CTRCNR1I2ALDH1A1
SCHEMBL9615852 0.78 ALDH1A1 (0.43) CSNK1ECNR2CNR1ALDH1A1
SCHEMBL15410683 0.78 ALDH1A1 (0.43) CSNK1ECNR2CNR1ALDH1A1
SCHEMBL6951984 0.77 SLC7A5 (0.41) CSNK1ESLC6A4CHRM1ADRA2BSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6743776-B2 ANTIFUNGAL, BETA-1,3-GLUCAN SYNTHASE INHIBITOR, PNEUMOCYSTIS CARINII; AMIDATION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-01 US disclosed
US-20020193560-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY ASTELLAS PHARMA INC. (JP) 2002-12-19 US disclosed
EP-0941236-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-09-15 EP disclosed
WO-1998023637-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193560-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY NGLY1, CHIT1, MANBA LTA4H 2161/4885CSNK1E 1065/4885CNR2 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.